Clinical improvement · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of clinical remission · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No of episodes of acute pouchitis · Patients with ileal pouch‐anal anastomosis
It is very uncertain whether clostridium probiotic changes no of episodes of acute pouchitis compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical improvement compared with budesonide enema (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No episodes of acute pouchitis · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of AAD · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention probably leads to lower incidence of AAD (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of AAD: Probiotic dose (≥5 billion CFUs of probiotics/day) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention probably leads to lower incidence of AAD: Probiotic dose (≥5 billion CFUs of probiotics/day) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention showed no clear difference in adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Duration of diarrhea (days) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
1 finding from 1 review
Intervention not reported
Microbiome characteristics · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).
1 finding from 1 review
RR 0.71 [0.46, 1.1]
110 participants
Low
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review